Globally, over 58 million people are estimated to have hepatitis C virus (HCV). Despite the availability of all-oral, short-course direct-acting antivirals (DAAs) that treat all HCV genotypes, nearly half a million people die from this preventable, curable infection each year…
The purpose of this new publication is to provide information for you and your community. The Activist Guide aims to provide a deeper focus on diagnosis with updated information about the steps and different technologies involved in diagnosing a person with hepatitis C.
This is a joint statement from TAG and Health GAP October 16, 2019 – Although Speaker Nancy Pelosi’s bill to increase affordable access to medicines in the U.S., H.R. 3, offers halting, partial steps to reduce drug prices for some…
Pipeline Report provides an overview of research and provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).
Treatment Action Group (TAG) strongly opposes the administration’s finalized rule “Inadmissibility on Public Charge Grounds.” This rule, which goes into effect on October 15, 2019, dangerously expands the definition of immigrants who are ineligible for admission into the U.S. or adjustment of status to include those who seek basic public services for health, nutrition, and housing.
June 2013 By Karyn Kaplan As rich countries prepare for a hepatitis C virus (HCV) treatment revolution, people in low- and middle-income countries (LMICs) remain without access to information, prevention tools, diagnostics, care, and treatment. A growing movement of global…
Streamlining HCV Treatment By Tracy Swan Treatment for hepatitis C virus (HCV) is becoming simpler, shorter, and more effective. All-oral combinations of direct-acting antivirals (DAAs) have pushed cure rates in HCV genotype 1 to over 90 percent. Still, we are…
June 2013 By Tracy Swan Thanks to Jules Levin The pace of, and progress in, hepatitis C virus (HCV) drug development are astonishing. In April 2011, proof-of-concept for safe, effective, peginterferon-free HCV treatment was announced. Since then, numerous trials have…
By Karyn Kaplan and Tracy Swan How can governments and donors effectively address HCV if pharma refuses to drop drug prices? —Paata Sabelashvili, Activist, Georgian Harm Reduction Network Keeping up with the rapid pace of hepatitis C drug development,…
July 2014 By Tracy Swan Thanks to Jules Levin This update includes presentations from the American Association for the Study of Liver Diseases (AASLD) Meeting, the Conference on Retroviruses and Opportunistic Infections (CROI), the European Association for the Study of…